ClinicalTrials.govpublic full text
Carfilzomib in Treatment Patients Under 65 Years With High Risk Smoldering Multiple Myeloma
smoldering multiple myeloma, carfilzomib, lenalidomide, melphalan, dexamethasone, autologous stem cell transplantation, interventional, phase2
This document is indexed with metadata only — full text is not available in the archive for this record.
Open the official source ↗
Related documents
Record · ID 861158
Retrieved via
Conceptio — every document is proof-bundled with source, license, and retrieval metadata.